Immutep Halts Phase III Lung Cancer Trial After Futility Analysis, Shares Plunge 88%
核心洞察
Immutep discontinued its pivotal Phase III TACTI-004 trial evaluating eftilagimod alfa in first-line non-small cell lung cancer after an independent interim analysis concluded the study was unlikely to meet its primary endpoints.
The trial discontinuation triggered one of the most dramatic share price reactions in the ASX biotech sector, with Immutep stock plunging around 88% and erasing the vast majority of the company's market value in a single trading session.
The global Phase III study was designed to enroll roughly 756 patients across more than 150 clinical sites in over 25 countries, testing efti in combination with chemotherapy and Keytruda.
Australian biotech Immutep Ltd abruptly halted its pivotal Phase III lung cancer study after an independent interim analysis concluded the trial was unlikely to meet its primary endpoints, triggering one of the most dramatic share price collapses in the ASX biotech sector in years.
The Sydney-based immunotherapy developer announced that its Phase III TACTI-004 trial evaluating eftilagimod alfa — known as "efti" — in first-line non-small cell lung cancer would be discontinued following recommendations from the trial's Independent Data Monitoring Committee. By Friday afternoon, Immutep stock had plunged around 88%, erasing the vast majority of the company's market value in a single trading session.
Futility Analysis Triggers Trial Halt
The trial's Independent Data Monitoring Committee recommended discontinuation after reviewing safety and efficacy data during a planned interim futility analysis — a checkpoint designed to determine whether continuing the study still has a realistic chance of success. When such analyses suggest the probability of meeting the study's goals is too low, continuing can become both scientifically and financially unjustifiable.
"We are very disappointed and surprised with the outcome of the futility analysis, in light of efti's performance in every other clinical trial," said Chief Executive Marc Voigt. The company said it will conduct a full review of the available data to understand what went wrong and determine the next steps for the program.
Immutep said enrollment in the trial will be halted and the study will now be wound down in an orderly fashion, including patient follow-up and site close-out procedures.
Ambitious Global Study Design
TACTI-004 was one of the most ambitious studies in Immutep's pipeline. The global Phase III trial was designed to enroll roughly 756 patients across more than 150 clinical sites in over 25 countries, testing efti in combination with chemotherapy and the blockbuster immunotherapy drug Keytruda in patients with advanced or metastatic non-small cell lung cancer.
The study targeted patients regardless of PD-L1 expression and aimed to demonstrate improvements in both progression-free survival and overall survival — the dual primary endpoints required to support regulatory approval. Efti itself is designed to activate antigen-presenting cells through the LAG-3 (搜索) pathway, helping stimulate both the adaptive and innate immune systems to mount an anti-tumor response.
Financial Impact and Pipeline Implications
One immediate consequence of stopping the study is financial relief. Clinical trials are among the most expensive activities in drug development, and discontinuing the program will reduce Immutep's near-term spending. The company said the decision is expected to extend its cash runway well beyond the previously guided timeframe of the second quarter of calendar 2027.
The share price collapse reflects how central the program had become to Immutep's investment thesis. Biotech valuations often hinge on a small number of pivotal clinical trials, and when a Phase III study fails — particularly one targeting a major cancer indication — the impact on market value can be immediate and severe.
Remaining Pipeline Opportunities
Despite the setback, efti continues to be evaluated in other tumor types. The drug is still being studied in several other indications, including head and neck cancer, breast cancer and soft-tissue sarcoma, and has received Fast Track designation from the US Food and Drug Administration in certain settings.
Whether those programs can rebuild confidence after such a dramatic clinical setback remains to be seen. The scale of Friday's sell-off caught attention because Immutep had attracted backing from prominent institutional investors, including funds associated with Regal Partners.
The episode serves as a stark illustration of the volatility inherent in biotech investing: years of development — and billions in market value — can hinge on a single trial result.